Istradefylline-13C,d3

Modify Date: 2024-01-09 19:18:30

Istradefylline-13C,d3 structure	Common Name	Istradefylline-13C,d3
	CAS Number	2749234-46-4	Molecular Weight	388.44
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₉₁₃CH₂₁D₃N₄O₄	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Istradefylline-13C,d3

Istradefylline-13C,d3 is the 13C- and deuterium labeled. Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease.

Name	Istradefylline-13C,d3

Description	Istradefylline-13C,d3 is the 13C- and deuterium labeled. Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease.
Related Catalog	Research Areas >> Neurological Disease Signaling Pathways >> GPCR/G Protein >> Adenosine Receptor
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[86].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [2]. Chen JF, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 2001 May 15;21(10):RC143. [3]. Shiozaki S, et al. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl). 1999 Nov;147(1):90-5. [4]. Kanda T, et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol. 2000 Apr;162(2):321-7. [5]. Brambilla R, et al. Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia. 2003 Aug;43(2):190-4. [6]. Mihara T, et al. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition. J Pharm

Molecular Formula	C₁₉₁₃CH₂₁D₃N₄O₄
Molecular Weight	388.44